Abstract:Introduction: Many studies identified that smokers had lower body mass index (BMI) than non-smokers, but the underlying mechanisms are not well understood. Hypothesis: An untargeted metabolomics study will identify novel mechanisms underlying smoking associated weight loss. Methods: We performed cross-sectional analyses among all 248 current smokers and 637 never smokers participated in the Bogalusa Heart Study 2016 survey. After stringent quality control and normalization, 1,202 plasma metabolites were assessed for mediation effects on smoking-BMI association after controlling for age, gender, race, education, drinking and physical activity. The collective mediation effects of metabolites were estimated by comparing the smoking-BMI associations before and after controlling for all significant metabolites after Bonferroni correction. Bidirectional Mendelian randomization analyses were then performed on a subset of participants (n=654) to delineate causal directions among smoking, BMI, and significant metabolites. We constructed multi-locus genetic risk scores (GRS) for smoking and BMI based on findings from published GWASs with a sample size of more than 250,000. Multivariable linear regression controlling for the same covariates as in the mediation analyses was used to estimate associations between smoking- and BMI-GRSs and the significant metabolites. Results: Compared to never smokers, current smokers had a 3.31 kg/m 2 (95% confidence interval [CI]: 2.15-4.47) lower BMI after adjusting for all covariables. A total of 40 metabolites significantly mediated and explained 90.7% of the smoking-BMI association. Seven of the significant metabolites were associated with smoking GRS but not BMI GRS, suggesting a true mediation role in the smoking-BMI association. The seven metabolites, including homoarginine (mediation beta=-0.49 kg/m 2 , 95% CI: -0.78 to -0.26), 1-oleoyl-GPE (18:1) (mediation beta=-0.44 kg/m 2 , 95% CI: -0.72 to -0.22), 1-linoleoyl-GPE (18:2)* (mediation beta=-0.59 kg/m 2 , 95% CI: -0.90 to -0.32), beta-cryptoxanthin (mediation beta=0.53 kg/m 2 , 95% CI: 0.27 to 0.83), 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) (mediation beta=0.39 kg/m 2 , 95% CI: 0.18 to 0.65), sphingomyelin (d18:2/21:0, d16:2/23:0)* (mediation beta=-0.54 kg/m 2 , 95% CI: -0.84 to -0.28), and sphingomyelin (d17:2/16:0, d18:2/15:0)* (mediation beta=-0.92 kg/m 2 , 95% CI: -1.30 to -0.59), mediated 36.3% of the association between current smoking and BMI. We also identified 6 metabolites significantly associated with BMI GRS but not with smoking GRS, and 2 significantly associated with both smoking- and BMI-GRSs. Conclusions: We identified 7 plasma metabolites that mediated a large proportion of the association between smoking and BMI.

Metabolic profiling of smoking, associations with type 2 diabetes and interaction with genetic susceptibility

Smoking and Diabetes: is the Association Mediated by Adiponectin, Leptin, or C-reactive Protein?

Smoking Status and Type 2 Diabetes, and Cardiovascular Disease: A Comprehensive Analysis of Shared Genetic Etiology and Causal Relationship

Association Between Environmental Tobacco Smoke Exposure and Risk of Type 2 Diabetes Mellitus in Chinese Female Never Smokers: A Population‐based Cohort Study

Smoking-related gut microbiota alteration is associated with obesity and obesity-related diseases: results from two independent cohorts with sibling comparison analyses

Smoking and coronary artery disease risk in patients with diabetes: A Mendelian randomization study

Active Cigarette Smoking Is Associated With an Exacerbation of Genetic Susceptibility to Diabetes

Conditional and Unconditional Genome-Wide Association Study Reveal Complicate Genetic Architecture of Human Body Weight and Impacts of Smoking

Early-life tobacco smoke exposure, genetic susceptibility and the risk of type 2 diabetes in adulthood: A large prospective cohort study

Smoking timing, genetic susceptibility and the risk of incident type 2 diabetes: A cohort study from the UK Biobank

Smoking induces coordinated DNA methylation and gene expression changes in adipose tissue with consequences for metabolic health

Circulating Fatty Acids and Genetic Predisposition to Type 2 Diabetes: Gene-Nutrient Interaction Analysis

1707-P: Maternal Smoking Around Birth, Offspring Genetic Susceptibility to Adiposity, and Risk of Type 2 Diabetes

Smoking and diabetes

Abstract P111: Untargeted Metabolomics Study And Bidirectional Mendelian Randomization Analyses Identified Novel Metabolites Mediating The Effect Of Current Smoking On Body Mass Index

Insights into the metabolic consequences of type 2 diabetes

Smoking is associated with impaired glucose regulation and a decrease in insulin sensitivity and the disposition index in first-degree relatives of type 2 diabetes subjects independently of the presence of metabolic syndrome

Metabolomics in human type 2 diabetes research

Genome-wide Interaction Study of Smoking Behavior and Non-Small Cell Lung Cancer Risk in Caucasian Population

Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events

The metabolic potential of inflammatory and insulinaemic dietary patterns and risk of type 2 diabetes